

IRON PH

CLINICAL TRIAL


PULMONARY HYPERTENSION

Pulmonary hypertension is a condition in which the blood pressure in the pulmonary arteries is elevated. This leads to symptoms such as **shortness of breath** and **reduced exercise capacity**, resulting in a lower quality of life.

IRON DEFICIENCY

Approximately **60%** of patients with pulmonary hypertension also suffer from iron deficiency. This iron deficiency worsens the symptoms.

Iron pills are often ineffective against iron deficiency in patients with pulmonary hypertension because of reduced iron absorption through the intestines. An **iron infusion** is effective against iron deficiency, but it is unclear whether it also helps alleviate the symptoms.



GOAL OF THE STUDY

The IRON-PH study will therefore investigate the **effect** of an **intravenous iron medication** ('ferric carboxymaltose') on the **exercise capacity** and **quality of life** of patients with pulmonary hypertension who have iron deficiency.

To do this, the study will include **306** patients who will be treated either with an iron infusion or with a placebo (inactive medication).

COURSE OF THE STUDY

- **Week 0:** medication administration, complete questionnaires, walk test, collect vital signs, blood collection, ECG
- **Week 4:** medication administration (if needed)
- **Week 12:** complete questionnaires, walk test, collect vital signs, blood collection
- **Week 24:** complete questionnaires, walk test, collect vital signs, blood collection

COSTS

There are **no additional costs** associated with participating in the study. All study specific examinations and treatments are free of charge. In addition, a **compensation of 25 euros per visit** will be provided.

Want more info?

Ask your doctor or scan the QR code
You can also email iron-ph@zol.be

